Results 131 to 140 of about 8,557 (171)

CT-P13: a safe and effective treatment for IBD [PDF]

Nature Reviews Gastroenterology & Hepatology, 2016
openaire   +1 more source

Response to: 'Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration’ by Marshall et al. [PDF]

, 2016
Emery, P, Ghil, J, Vencovský, J, Won Kang, J   +3 more
core   +1 more source

Biosimilar CT-P13 comparable to infliximab in active RA [PDF]

Nature Reviews Rheumatology, 2013
openaire   +1 more source

Clinical, Radiological and Pharmacokinetic Data of CT-P13 Subcutaneous in Individuals with Fistulizing Anoperineal Crohn's Disease. [PDF]

Dig Dis Sci
Fathallah N, Draullette M, Kirchgesner J, Paul S, Roblin X, Bourrier A, Haouari MA, Chambenois E, Morisset S, Seksik P, de Parades V.   +10 more
europepmc   +1 more source

Real-World Effectiveness and Safety of Infliximab Biosimilar CT-P13 for Rheumatic Diseases: A National Observational Cohort Study (ReFLECT). [PDF]

Adv Ther
Marotte H, Cantagrel A, Coury F, Schaeverbeke T, Assing M, Kessouri M, Brault Y, Fautrel B.   +7 more
europepmc   +1 more source

Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease. [PDF]

Eur J Hosp Pharm, 2022
Martín-Gutiérrez N, Sánchez-Hernández JG, Rebollo N, Pordomingo AF, Muñoz F, Otero MJ.   +5 more
europepmc   +1 more source

Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies. [PDF]

Inflamm Bowel Dis
Schreiber S, Colombel JF, Hanauer SB, Sandborn WJ, Danese S, Lee SJ, Kim SH, Bae YJ, Lee SH, Lee SG, Lee JH, Kim JM, Park GH, Lee J, Lee JH, Kim CY, Sands BE.   +16 more
europepmc   +1 more source

Efficacy and Safety of CT-P13 as First- and Second-Line Treatment in Patients with Ankylosing Spondylitis. [PDF]

J Clin Med
Uslu S, Gülle S, Sen G, Capar S, Senel S, Dalkılıc E, Akar S, Koca SS, Tufan A, Yazici A, Yilmaz S, Inanc N, Birlik M, Solmaz D, Cefle A, Goker B, Direskeneli H, Yolbas S, Steen Krogh N, Yilmaz N, Erten S, Bes C, Soysal Gündüz O, Oztürk MA, Haznedaroglu S, Yavuz S, Onen F, Sari I.   +27 more
europepmc   +1 more source

Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY). [PDF]

J Crohns Colitis
Colombel JF, Sandborn WJ, Schreiber S, Danese S, Kłopocka M, Kierkuś J, Kulynych R, Gonciarz M, Sołtysiak A, Smoliński P, Srećković S, Valuyskikh E, Lahat A, Horyński M, Gasbarrini A, Osipenko M, Borzan V, Kowalski M, Saenko D, Sardinov R, Lee SJ, Kim S, Bae Y, Lee S, Lee S, Lee JH, Kim JM, Park G, Lee J, Lee J, Ryu JY, Sands BE, Hanauer SB.   +32 more
europepmc   +1 more source

Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. [PDF]

, 2015
Cantini F, Conversano M, Delogu G, Garlaschi G, Goletti D, Iannone F, Matucci A, Nannini C, Niccoli L, Prignano F, SAFEBIO, SANDUZZI ZAMPARELLI, ALESSANDRO   +11 more
core   +1 more source